Protocol Ledger

NCT04102150 · Phase II · COMPLETED

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Interventional Phase II clinical trial protocol NCT04102150 sponsored by Daiichi Sankyo in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-21 Enrollment: 25 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04102150
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)25 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04102150
Protocol FieldVerified Registry Value
NCT IdentifierNCT04102150
Consolidated Lead SponsorDaiichi Sankyo
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment25 participants (ACTUAL)
Registered Start Date2019-11-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI